TOP TEN perturbations for NM_000317 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000317
Selected probe(set): 209694_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000317 (209694_at) across 5392 perturbations tested by GENEVESTIGATOR:

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):2.990715
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC?s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC?s of HIV-seronegative donors.

T-cell activation study 2 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):2.7196999
Number of Samples:2 / 2
Experimental T-cell activation study 2
CD4+ T-cell samples derived from PBMC?s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days..
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC?s of HIV-seronegative donors.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-1.9961767
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

sirolimus study 6 (light) / sirolimus study 6 (heavy)

Relative Expression (log2-ratio):1.9175091
Number of Samples:3 / 3
Experimental sirolimus study 6 (light)
Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the light polysome fraction. ATC code:
Control sirolimus study 6 (heavy)
Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the heavy polysome fraction. ATC code:

T-cell isolation study 11 / T-cell isolation study 6

Relative Expression (log2-ratio):1.7906914
Number of Samples:2 / 2
Experimental T-cell isolation study 11
CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20?C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.
Control T-cell isolation study 6
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):1.6955805
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

stem cell differentiation study 46 (BMP4, inhibitors) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):1.6572437
Number of Samples:3 / 3
Experimental stem cell differentiation study 46 (BMP4, inhibitors)
Extraembryonic cells differentiated from WA09 cells in chemically defined medium supplemented with BMP4 and inhibitors of activin and FGF2. Differentiation was performed in the absence of feeders cells and serum. Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then in CDM supplemented with BMP4 (10 ng/ml), an inhibitor of Alk4/5/7 receptors (type I Activin receptor-like kinase), SB431542 (10uM), and an inhibitor of FGF receptors, SU5402 (10uM), for 3-4 days.
Control normal embryonic stem cell sample (WA09)
WA09 embryonic stem cells cultivated in chemically defined medium (CDM). Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then further cultivated in CDM alone for 3-4 days. CDM consists of 50% Iscove?s Modified Dulbecco?s Medium and 50% F12 Ham?s nutrient mixture. It is devoid of serum and supplemented with insulin (7 ug/ml), transferrin (15 ug/ml), monothioglycerol (450 uM) and serum albumin (5 mg/ml).

Alzheimer's disease study 9 / normal pyramidal neuron (posterior cingulate)

Relative Expression (log2-ratio):-1.655303
Number of Samples:9 / 13
Experimental Alzheimer's disease study 9
Cortical layer III pyramidal neurons of the posterior cingulate of clinically and neuropathologically classified late-onset Alzheimer?s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent.
Control normal pyramidal neuron (posterior cingulate)
Cortical layer III pyramidal neurons of the posterior cingulate of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density.

pancreatic islet study 3 (re-differentiated; PPRF; 4d) / pancreatic islet study 3 (re-differentiated; NIH)

Relative Expression (log2-ratio):-1.6431084
Number of Samples:2 / 4
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 4d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control pancreatic islet study 3 (re-differentiated; NIH)
Pancreatic islet cells were expanded for 10 weeks and re-differentiated for 1 week according to National Institutes of Health (NIH) protocol. Re-differentiation phase: Expanded cells were cultured for 1 week in serum-free CMRL-1066 medium supplemented with insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml).

pancreatic islet study 3 (re-differentiated; PPRF; 2d) / pancreatic islet study 3 (re-differentiated; NIH)

Relative Expression (log2-ratio):-1.6341171
Number of Samples:2 / 4
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 2d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control pancreatic islet study 3 (re-differentiated; NIH)
Pancreatic islet cells were expanded for 10 weeks and re-differentiated for 1 week according to National Institutes of Health (NIH) protocol. Re-differentiation phase: Expanded cells were cultured for 1 week in serum-free CMRL-1066 medium supplemented with insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml).